SuperworthNovoCure EPS NVCR
Diluted earnings per share by quarter and over the last twelve months, from 2014.
- Last 12 months, to Jun 30, 2026
- −$1.30
- Latest quarter, Q2 FY26
- −$0.13
- Fiscal year 2025
- −$1.22
NovoCure's earnings per share was −$1.30 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.13.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.22 | n/a |
| FY2024 | −$1.56 | n/a |
| FY2023 | −$1.94 | n/a |
| FY2022 | −$0.88 | n/a |
| FY2021 | −$0.56 | −395% |
| FY2020 | $0.19 | n/a |
| FY2019 | −$0.08 | n/a |
| FY2018 | −$0.70 | n/a |
| FY2017 | −$0.70 | n/a |
| FY2016 | −$1.55 | n/a |
| FY2015 | −$6.61 | n/a |
| FY2014 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.13 | n/a | −$1.30 | |
| Q1 FY26 | −$0.62 | n/a | −$1.53 | |
| Q4 FY25 | −$0.22 | n/a | −$1.22 | |
| Q3 FY25 | −$0.33 | n/a | −$1.61 | |
| Q2 FY25 | −$0.36 | n/a | −$1.56 | |
| Q1 FY25 | −$0.31 | n/a | −$1.51 | |
| Q4 FY24 | −$0.61 | n/a | −$1.56 | |
| Q3 FY24 | −$0.28 | n/a | −$1.39 | |
| Q2 FY24 | −$0.31 | n/a | −$1.57 | |
| Q1 FY24 | −$0.36 | n/a | −$1.80 | |
| Q4 FY23 | −$0.44 | n/a | −$1.94 | |
| Q3 FY23 | −$0.46 | n/a | −$1.86 |
Against its peers
Companies in Medical - Instruments & Supplies nearest NovoCure's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| NVCRNovoCure | −$1.30 | |
| LMATLemaitre Vascular | $2.85 | +38% a year |
| EYENational Vision | $0.61 | |
| INSPInspire Medical Systems | $4.62 | +166% a year |
| CDRECadre | $0.81 | −14% a year |
| UFPTUFP Technologies | $9.28 | +8% a year |
| BVSBioventus | $0.77 | |
| STAAStaar Surgical | $0.07 | |
| IRMDIradimed | $1.79 | +10% a year |
| ATRCAtriCure | $0.21 | |
| WRBYWarby Parker | $0.07 | |
| Peer median | $0.79 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on NovoCure
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.